Fundraising Fox

ChromaCode

Carlsbad, US · Founded 2012 · Delaware corporation · 18 employees on LinkedIn · 9 known investors

ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

PFPaul Flook
Paul FlookinPresident and CEO
GJ
Gregory J. GoschExecutive
LR
Lynne RollinsExecutive
AR
Aditya RajagopalNamed on SEC filing
AS
Axel SchererNamed on SEC filing

Board

JKJustin Klein
Justin Kleinin𝕏Board directorCo-Founder and Managing Partner at Vensana Capital
JC
James C. BlairinBoard directorPartner at Domain Associates
AG
Alexander G. DickinsonBoard director

Investors · 9

Adjuvant CapitalNew York · $10M – $25M
Global BrainTokyo · $100K – $184M
Moore Venture PartnersSan Diego
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Windham Capital PartnersNew York · $1M – $5M
Domain AssociatesreportedPrinceton · $200K – $15M
Domain PartnersreportedPrinceton
Northpond VenturesreportedBethesda · $100K – $5M
Vensana Capitalreported · 2 sourcesMinneapolisvia Justin Klein · board

Funding

SEC filings, press & company announcements

$94.2M disclosed across 5 of 7 rounds · 2017–2025

▶$3.8MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aditya RajagopalDirector
  • Paul FlookExecutive Officer, Director
  • Justin KleinDirector
Offering amount
$5M
Amount sold
$3.8M
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38MraisedFeb 2023 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark McDonoughExecutive Officer, Director
  • Justin KleinDirector
  • Pat SmerkersDirector
  • Alexander G. DickinsonDirector
  • Kevin O'BoyleDirector
  • Carol GallagherDirector
  • Aditya RajagopalDirector
  • Jenny YipDirector
Offering amount
$43M
Amount sold
$38M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38.6MraisedDec 2020 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jenny YipDirector
  • Lynne RollinsExecutive Officer
  • Pat SmerkersDirector
  • Carol GallagherDirector
  • James C. BlairDirector
  • Alexander G. DickinsonDirector
  • Aditya RajagopalDirector
  • Gregory J. GoschExecutive Officer, Director
Offering amount
$41.2M
Amount sold
$38.6M
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedApr 2019 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James C. BlairDirector
  • Carol GallagherDirector
  • Alexander G. DickinsonDirector
  • Gregory J. GoschExecutive Officer, Director
  • Aditya RajagopalDirector
  • Lynne RollinsExecutive Officer
Offering amount
$3.5M
Amount sold
$1.8M
First sale
Apr 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedApr 2017 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • James C. BlairDirector
  • Gregory J. GoschExecutive Officer, Director
  • Peter Justin KleinDirector
  • Axel SchererDirector
  • Alexander G. DickinsonDirector
  • Lynne RollinsExecutive Officer
Offering amount
$12.1M
Amount sold
$12M
First sale
Apr 2017
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Transcode Therapeutics5 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
JUMPCODE Genomics4 shared keywordsJumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.

Companies competing with ChromaCode for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

ChromaCode Announces Strategic Investment to Advance Development and Application of HDPCR Platform Technology for Use in Oncology Genomicsprnewswire.com · Jun 2023Carlsbad’s ChromaCode raises $38 million to pursue low-cost testing platform for coronavirussandiegouniontribune.com · May 2020ChromaCode Raises $10 Million Series C Financing From Adjuvant Capitalprnewswire.com · May 2020ChromaCode Raises $28M in Series C Funding - FinSMEsfinsmes.com · Dec 2019ChromaCode raises USD12m in Series B fundraising - Private Equity Wireprivateequitywire.co.uk · Apr 2017

Frequently asked questions

What does ChromaCode do?
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
Who are ChromaCode's investors?
ChromaCode's investors include Adjuvant Capital, Global Brain, Moore Venture Partners, New Enterprise Associates (NEA), Windham Capital Partners, Domain Associates, Domain Partners, Northpond Ventures and 1 more.
How much funding has ChromaCode raised?
ChromaCode has disclosed $94.2M raised across 5 of its 7 known rounds.
Where is ChromaCode headquartered?
ChromaCode is headquartered in Carlsbad, US.